ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

B Vitamins May Protect Against Damaging Effects of Air Pollution, and Improve Cognition and Psychiat...

Relief for IBS, Colitis, Crohn’s And More

Can Magnesium Relieve Your Tinnitus?

Restless Leg Syndrome (RLS) - are you running a marathon each night?

Resveratrol Proven to Slow Brain Aging

Magnesium Protects Against Stroke, Heart Disease and Diabetes

Fruits and vegetables' latest superpower? Lowering blood pressure

Neroli Oil: The Pleasantly Fragrant Citrus Oil

Prenatal vitamin D could help prevent autism in children

Restoring NAD+ could reduce DNA damage accumulation

 
Print Page
Email Article

Celebrex® Study Shows Once-daily Dose As Effective As Twice-daily Dose for Treating Osteoarthritis

  [ Not Yet Rated ]   [ Discuss This Article ]
By News Release • www.ProHealth.com • April 6, 2000


SUMMARY: The results show that in all efficacy measures, both a once a day dose and a twice a day dose of Celebrex are equally beneficial for Ostearthritis (OA) patients. Researchers confirmed that the 200 mg once-daily regimen is effective and safe in treating OA. This offers added convenience and ease for patients who would prefer a once-daily dose

CHICAGO, April 6 /PRNewswire/ -- A recently published study of almost 700 osteoarthritis (OA) patients has found that a single daily dose (QD) of 200 mg of Celebrex ® (celecoxib capsules) is just as effective and safe as two daily doses (BID) of 100 mg each for the treatment of the pain and inflammation of OA.

The primary objective of this prospective, randomized, placebo-controlled, double-blind, outpatient study was to compare the efficacy of a once-daily regimen of Celebrex (200 mg QD) to the 100 mg BID regimen in treating the signs and symptoms of OA. Six hundred and eighty-six patients with OA of the knee in a flare state were enrolled in this parallel-group, multicenter study. Patients were randomly assigned to receive Celebrex 100 mg BID, Celebrex 200 mg QD, or placebo for a six-week treatment period. The results show that in all efficacy measures, both doses of Celebrex produced clinical improvement in the signs and symptoms of OA that were superior to those seen with placebo and essentially indistinguishable from each other.

Commenting on the study's significance, Gary W. Williams, M.D., lead author and head of the Division of Rheumatology at the Scripps Clinic, in La Jolla, California said, "We have confirmed that the 200 mg once-daily regimen is effective and safe in treating OA. This offers added convenience and ease for patients who would prefer a once-daily dose."

Physicians' current prescribing behavior is consistent with these findings; 83 percent of physicians prescribing Celebrex are choosing the once-daily regimen.(1)

Celebrex is the first COX-2 specific inhibitor approved by the U.S. Food and Drug Administration for the treatment of osteoarthritis and adult rheumatoid arthritis, and is co-promoted by Searle and Pfizer Inc. Patients who have a known allergic reaction to celecoxib, certain sulfa drugs called sulfonamides, aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) should not use Celebrex. As with all NSAIDs, serious gastrointestinal toxicity can occur with or without warning symptoms. In clinical trials, the most common side effects of Celebrex were dyspepsia, diarrhea and abdominal pain, which were generally mild to moderate.
Searle, the leading arthritis company worldwide, is the largest provider of branded prescription arthritis medicines in the United States and is the first company to bring COX-2 technology to the marketplace.

Source: Pharmacia Corporation



Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra ATP+, Double Strength Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Restoring Gut Health: How to Create a Firewall Against Toxins Entering the Gut Wall Restoring Gut Health: How to Create a Firewall Against Toxins Entering the Gut Wall
The Curcumin Revolution: 'Golden' Ticket to Better Health The Curcumin Revolution: 'Golden' Ticket to Better Health
Safely Burn Away Body Fat Safely Burn Away Body Fat
Help for Soreness and Swelling: What Do Silkworms Have to Do With It? Help for Soreness and Swelling: What Do Silkworms Have to Do With It?
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map